{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:48:47Z","timestamp":1790743727950,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>To determine whether the neutralization activity of monoclonal antibodies, convalescent sera and vaccine-elicited sera was affected by the top five epidemic SARS-CoV-2 variants in the UK, including D614G+L18F+A222V, D614G+A222V, D614G+S477N, VOC-202012\/01(B.1.1.7) and D614G+69-70del+N439K, a pseudovirus-neutralization assay was performed to evaluate the relative neutralization titers against the five SARS-CoV-2 variants and 12 single deconvolution mutants based on the variants. In this study, 18 monoclonal antibodies, 10 sera from convalescent COVID-19 patients, 10 inactivated-virus vaccine-elicited sera, 14 mRNA vaccine-elicited sera, nine RBD-immunized mouse sera, four RBD-immunized horse sera, and four spike-encoding DNA-immunized guinea pig sera were tested and analyzed. The N501Y, N439K, and S477N mutations caused immune escape from nine of 18 mAbs. However, the convalescent sera, inactivated virus vaccine-elicited sera, mRNA vaccine-elicited sera, spike DNA-elicited sera, and recombinant RBD protein-elicited sera could still neutralize these variants (within three-fold changes compared to the reference D614G variant). The neutralizing antibody responses to different types of vaccines were different, whereby the response to inactivated-virus vaccine was similar to the convalescent sera.<\/jats:p>","DOI":"10.3389\/fimmu.2021.687869","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T09:18:52Z","timestamp":1623921532000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom"],"prefix":"10.3389","volume":"12","author":[{"given":"Jiajing","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2895-3","article-title":"Spike Mutation D614G Alters SARS-CoV-2 Fitness","volume":"592","author":"Plante","year":"2021","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe5901","article-title":"Transmission of SARS-CoV-2 on Mink Farms Between Humans and Mink and Back to Humans","volume":"371","author":"Oude Munnink","year":"2021","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg6105","article-title":"Neutralization of SARS-CoV-2 Lineage B.1.1.7 Pseudovirus by BNT162b2 Vaccine-Elicited Human Sera","volume":"371","author":"Muik","year":"2021","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01255-3","article-title":"Sixteen Novel Lineages of SARS-CoV-2 in South Africa","volume":"27","author":"Tegally","year":"2021","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3201\/eid2704.210183","article-title":"Imported SARS-CoV-2 Variant P.1 in Traveler Returning From Brazil to Italy","volume":"27","author":"Maggi","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.05.430003","article-title":"Neutralization of Viruses With European, South African, and United States SARS-CoV-2 Variant Spike Proteins by Convalescent Sera and BNT162b2 mRNA Vaccine-Elicited Antibodies","author":"Tada","year":"2021","journal-title":"bioRxiv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.042","article-title":"Sars-CoV-2 501y.V2 Variants Lack Higher Infectivity But Do Have Immune Escape","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc5881","article-title":"Structural Basis for Neutralization of SARS-CoV-2 and SARS-CoV by a Potent Therapeutic Antibody","volume":"369","author":"Lv","year":"2020","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent Neutralizing Antibodies Against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients\u2019 B Cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults Aged 18-59 Years: A Randomised, Double-Blind, Placebo-Controlled, Phase 1\/2 Clinical Trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0394-5","article-title":"Quantification of SARS-CoV-2 Neutralizing Antibody by a Pseudotyped Virus-Based Assay","volume":"15","author":"Nie","year":"2020","journal-title":"Nat Protoc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2381-y","article-title":"A Human Neutralizing Antibody Targets the Receptor-Binding Site of SARS-Cov-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an Inactivated Vaccine Candidate, Bbibp-CorV, With Potent Protection Against SARS-Cov-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the Mrna-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01270-4","article-title":"Neutralization of SARS-CoV-2 Spike 69\/70 Deletion, E484K and N501Y Variants by BNT162b2 Vaccine-Elicited Sera","volume":"27","author":"Xie","year":"2021","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c Mice for Testing Vaccine Efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.05.429982","article-title":"Furin Cleavage of the SARS-CoV-2 Spike is Modulated by O-Glycosylation","author":"Zhang","year":"2021","journal-title":"bioRxiv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-208849\/v1","article-title":"SARS-Cov-2 European Resurgence Foretold: Interplay of Introductions and Persistence by Leveraging Genomic and Mobility Data","author":"Lemey","year":"2021","journal-title":"Res Sq"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 Variants Escape Neutralization by Vaccine-Induced Humoral Immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","article-title":"Identification of SARS-CoV-2 Spike Mutations That Attenuate Monoclonal and Serum Antibody Neutralization","volume":"29","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.cell.2021.01.037","article-title":"Circulating SARS-CoV-2 Spike N439K Variants Maintain Fitness While Evading Antibody-Mediated Immunity","volume":"184","author":"Thomson","year":"2021","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 Mrna Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2: A Preliminary Report of a Phase 1\/2, Single-Blind, Randomised Controlled Trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1038\/s41467-020-17972-1","article-title":"A Single Dose of an Adenovirus-Vectored Vaccine Provides Protection Against SARS-CoV-2 Challenge","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and Immunogenicity of a Recombinant Tandem-Repeat Dimeric RBD-Based Protein Subunit Vaccine (ZF2001) Against COVID-19 in Adults: Two Randomised, Double-Blind, Placebo-Controlled, Phase 1 and 2 Trials","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6284","article-title":"DNA Vaccine Protection Against SARS-CoV-2 in Rhesus Macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104868","article-title":"Immunoglobulin Fragment F(Ab\u2019)2 Against RBD Potently Neutralizes SARS-Cov-2 in vitro","volume":"182","author":"Pan","year":"2020","journal-title":"Antiviral Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.687869\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T09:18:56Z","timestamp":1623921536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.687869\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2021.687869"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.687869","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"article-number":"687869"}}